Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

In the coming years, Bristol Myers Squibb, Merck, Amgen, Novartis and AstraZeneca are staring down the greatest level of ...

GSK confirmed that the program is progressing to Phase 3 in ... regulations and governmental policies, pressures from increasing competition and consolidation in the company's industry, the effects of ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways ... that we face significant competition from other biotechnology and pharmaceutical ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Dynavax is giving up work on its combination vaccine for tetanus, diphtheria and acellular pertussis (Tdap) after mulling phase 1 data for the shot. | Dynavax is giving up on its combination vaccine ...

The drug is positioned as a follow-up product to GSK’s blockbuster Advair/Seretide, but the company is now facing generic competition against its older drug, plus new rivals from the likes of ...

It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

Nigeria, the giant of Africa, has recently experienced a great downturn in its economy, leading to the exodus of several ...

It may be based in the US but Workday (NASDAQ: WDAY) is critical to the FTSE 100. As a global leader in business management software, it helps some of our nation’s top companies manage their ...

Gilead Sciences, Inc. GILD reported better-than-expected third-quarter results and raised its annual earnings guidance.